Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METEOR: Cabozantinib vs Everolimus in Advanced RCC
NCT01865747Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Exelixis, Inc.. Started Jun 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01865747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865747.